Literature DB >> 28874376

Genomics and Susceptibility Profiles of Extensively Drug-Resistant Pseudomonas aeruginosa Isolates from Spain.

Ester Del Barrio-Tofiño1, Carla López-Causapé1, Gabriel Cabot1, Alba Rivera2, Natividad Benito2, Concepción Segura3, María Milagro Montero3, Luisa Sorlí3, Fe Tubau4, Silvia Gómez-Zorrilla4, Nuria Tormo5, Raquel Durá-Navarro5, Esther Viedma6, Elena Resino-Foz6, Marta Fernández-Martínez7, Claudia González-Rico7, Izaskun Alejo-Cancho8, Jose Antonio Martínez8, Cristina Labayru-Echverria9, Carlos Dueñas9, Ignacio Ayestarán1, Laura Zamorano1, Luis Martinez-Martinez10,11, Juan Pablo Horcajada3, Antonio Oliver12.   

Abstract

This study assessed the molecular epidemiology, resistance mechanisms, and susceptibility profiles of a collection of 150 extensively drug-resistant (XDR) Pseudomonas aeruginosa clinical isolates obtained from a 2015 Spanish multicenter study, with a particular focus on resistome analysis in relation to ceftolozane-tazobactam susceptibility. Broth microdilution MICs revealed that nearly all (>95%) of the isolates were nonsusceptible to piperacillin-tazobactam, ceftazidime, cefepime, aztreonam, imipenem, meropenem, and ciprofloxacin. Most of them were also resistant to tobramycin (77%), whereas nonsusceptibility rates were lower for ceftolozane-tazobactam (31%), amikacin (7%), and colistin (2%). Pulsed-field gel electrophoresis-multilocus sequence typing (PFGE-MLST) analysis revealed that nearly all of the isolates belonged to previously described high-risk clones. Sequence type 175 (ST175) was detected in all 9 participating hospitals and accounted for 68% (n = 101) of the XDR isolates, distantly followed by ST244 (n = 16), ST253 (n = 12), ST235 (n = 8), and ST111 (n = 2), which were detected only in 1 to 2 hospitals. Through phenotypic and molecular methods, the presence of horizontally acquired carbapenemases was detected in 21% of the isolates, mostly VIM (17%) and GES enzymes (4%). At least two representative isolates from each clone and hospital (n = 44) were fully sequenced on an Illumina MiSeq. Classical mutational mechanisms, such as those leading to the overexpression of the β-lactamase AmpC or efflux pumps, OprD inactivation, and/or quinolone resistance-determining regions (QRDR) mutations, were confirmed in most isolates and correlated well with the resistance phenotypes in the absence of horizontally acquired determinants. Ceftolozane-tazobactam resistance was not detected in carbapenemase-negative isolates, in agreement with sequencing data showing the absence of ampC mutations. The unique set of mutations responsible for the XDR phenotype of ST175 clone documented 7 years earlier were found to be conserved, denoting the long-term persistence of this specific XDR lineage in Spanish hospitals. Finally, other potentially relevant mutations were evidenced, including those in penicillin-binding protein 3 (PBP3), which is involved in β-lactam (including ceftolozane-tazobactam) resistance, and FusA1, which is linked to aminoglycoside resistance.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  Pseudomonas aeruginosa; extensively drug resistant; high-risk clones; whole-genome sequencing

Mesh:

Substances:

Year:  2017        PMID: 28874376      PMCID: PMC5655108          DOI: 10.1128/AAC.01589-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  77 in total

1.  Emergence of a mutL mutation causing multilocus sequence typing-pulsed-field gel electrophoresis discrepancy among Pseudomonas aeruginosa isolates from a cystic fibrosis patient.

Authors:  María García-Castillo; Luis Máiz; María-Isabel Morosini; Mercedes Rodríguez-Baños; Lucrecia Suarez; Ana Fernández-Olmos; Fernando Baquero; Rafael Cantón; Rosa del Campo
Journal:  J Clin Microbiol       Date:  2012-02-08       Impact factor: 5.948

2.  Avibactam and class C β-lactamases: mechanism of inhibition, conservation of the binding pocket, and implications for resistance.

Authors:  S D Lahiri; M R Johnstone; P L Ross; R E McLaughlin; N B Olivier; R A Alm
Journal:  Antimicrob Agents Chemother       Date:  2014-07-14       Impact factor: 5.191

3.  Fast gapped-read alignment with Bowtie 2.

Authors:  Ben Langmead; Steven L Salzberg
Journal:  Nat Methods       Date:  2012-03-04       Impact factor: 28.547

4.  Optimizing intravenous fosfomycin dosing in combination with carbapenems for treatment of Pseudomonas aeruginosa infections in critically ill patients based on pharmacokinetic/pharmacodynamic (PK/PD) simulation.

Authors:  O Asuphon; P Montakantikul; J Houngsaitong; P Kiratisin; P Sonthisombat
Journal:  Int J Infect Dis       Date:  2016-07-11       Impact factor: 3.623

5.  In Vivo Emergence of Resistance to Novel Cephalosporin-β-Lactamase Inhibitor Combinations through the Duplication of Amino Acid D149 from OXA-2 β-Lactamase (OXA-539) in Sequence Type 235 Pseudomonas aeruginosa.

Authors:  Pablo A Fraile-Ribot; Xavier Mulet; Gabriel Cabot; Ester Del Barrio-Tofiño; Carlos Juan; José L Pérez; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

6.  Development of colistin resistance in pmrA-, phoP-, parR- and cprR-inactivated mutants of Pseudomonas aeruginosa.

Authors:  Ji-Young Lee; Eun Seon Chung; In Young Na; Hyunkeun Kim; Dongwoo Shin; Kwan Soo Ko
Journal:  J Antimicrob Chemother       Date:  2014-07-02       Impact factor: 5.790

7.  Efficacy and potential for resistance selection of antipseudomonal treatments in a mouse model of lung infection by hypermutable Pseudomonas aeruginosa.

Authors:  M D Maciá; N Borrell; M Segura; C Gómez; J L Pérez; A Oliver
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

Review 8.  Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms.

Authors:  Philip D Lister; Daniel J Wolter; Nancy D Hanson
Journal:  Clin Microbiol Rev       Date:  2009-10       Impact factor: 26.132

9.  Nosocomial dissemination of VIM-2-producing ST235 Pseudomonas aeruginosa in Lithuania.

Authors:  G Mikucionyte; L Zamorano; A Vitkauskiene; C López-Causapé; C Juan; X Mulet; A Oliver
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-12-05       Impact factor: 3.267

10.  Pseudomonas aeruginosa: resistance to the max.

Authors:  Keith Poole
Journal:  Front Microbiol       Date:  2011-04-05       Impact factor: 5.640

View more
  43 in total

1.  Predictors of Mortality in Bloodstream Infections Caused by Pseudomonas aeruginosa and Impact of Antimicrobial Resistance and Bacterial Virulence.

Authors:  Raúl Recio; Mikel Mancheño; Esther Viedma; Jennifer Villa; María Ángeles Orellana; Jaime Lora-Tamayo; Fernando Chaves
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

2.  Hypermutator Pseudomonas aeruginosa Exploits Multiple Genetic Pathways To Develop Multidrug Resistance during Long-Term Infections in the Airways of Cystic Fibrosis Patients.

Authors:  C A Colque; A G Albarracín Orio; S Feliziani; R L Marvig; A R Tobares; H K Johansen; S Molin; A M Smania
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

Review 3.  Critical analysis of antibacterial agents in clinical development.

Authors:  Ursula Theuretzbacher; Karen Bush; Stephan Harbarth; Mical Paul; John H Rex; Evelina Tacconelli; Guy E Thwaites
Journal:  Nat Rev Microbiol       Date:  2020-03-09       Impact factor: 60.633

Review 4.  Resistance to Novel β-Lactam-β-Lactamase Inhibitor Combinations: The "Price of Progress".

Authors:  Krisztina M Papp-Wallace; Andrew R Mack; Magdalena A Taracila; Robert A Bonomo
Journal:  Infect Dis Clin North Am       Date:  2020-09-30       Impact factor: 5.982

5.  Evolution of the Pseudomonas aeruginosa Aminoglycoside Mutational Resistome In Vitro and in the Cystic Fibrosis Setting.

Authors:  Carla López-Causapé; Rosa Rubio; Gabriel Cabot; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

6.  Multicenter Evaluation of the Etest Gradient Diffusion Method for Ceftolozane-Tazobactam Susceptibility Testing of Enterobacteriaceae and Pseudomonas aeruginosa.

Authors:  Adam L Bailey; Tom Armstrong; Hari-Prakash Dwivedi; Gerald A Denys; Janet Hindler; Shelley Campeau; Maria Traczewski; Romney Humphries; C A Burnham
Journal:  J Clin Microbiol       Date:  2018-08-27       Impact factor: 5.948

7.  Mechanisms of Resistance to Ceftolozane/Tazobactam in Pseudomonas aeruginosa: Results of the GERPA Multicenter Study.

Authors:  Damien Fournier; Romain Carrière; Maxime Bour; Emilie Grisot; Pauline Triponney; Cédric Muller; Jérôme Lemoine; Katy Jeannot; Patrick Plésiat
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

8.  PsrA Regulator Connects Cell Physiology and Class 1 Integron Integrase Gene Expression Through the Regulation of lexA Gene Expression in Pseudomonas spp.

Authors:  Katarina D Novovic; Milka J Malesevic; Brankica V Filipic; Nemanja L Mirkovic; Marija S Miljkovic; Milan O Kojic; Branko U Jovčić
Journal:  Curr Microbiol       Date:  2019-01-25       Impact factor: 2.188

9.  Efficacy of Ceftolozane-Tazobactam in Combination with Colistin against Extensively Drug-Resistant Pseudomonas aeruginosa, Including High-Risk Clones, in an In Vitro Pharmacodynamic Model.

Authors:  María Montero; Sandra Domene Ochoa; Carla López-Causapé; Brian VanScoy; Sonia Luque; Luisa Sorlí; Núria Campillo; Ariadna Angulo-Brunet; Eduardo Padilla; Núria Prim; Virginia Pomar; Alba Rivera; Santiago Grau; Paul G Ambrose; Antonio Oliver; Juan P Horcajada
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

10.  Production of Norspermidine Contributes to Aminoglycoside Resistance in pmrAB Mutants of Pseudomonas aeruginosa.

Authors:  Arnaud Bolard; Monika Schniederjans; Susanne Haüssler; Pauline Triponney; Benoît Valot; Patrick Plésiat; Katy Jeannot
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.